Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CytRx, TriLink Biotechnologies Inc. deal

CYTR's RXi Pharmaceuticals Corp. subsidiary received an exclusive license

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE